Showing 1-10 of 2439 results for "".

• Daniel Friedman, MD, MSc
  https://practicalneurology.com/profiles/daniel-friedman-md-msc/7vwrep/
• Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Funding 
  https://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/
  The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and
• Award Recipients Recognized at 2025 International MDS Conference
  https://practicalneurology.com/news/award-recipients-recognized-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/2483939/
  The International Parkinson’s Disease and Movement Disorders Society (MDS) has recognized recipients of the 2025 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The award
• Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosis
  https://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/
  As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
• Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosis
  https://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/
  In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
• Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trial
  https://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/
  In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
• FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatment
  https://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/
  The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
• Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Rate
  https://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/
  In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
• Remembering Ronald DeVere, MD, FAAN
  https://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/
  Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
• Cell Therapy for ALS Associated with Increased Survival at 5 Years
  https://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/
  Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from

• Prev
• 1
• 2
• 3
• …
• 243
• 244
• Next